SSRI for Generalized Anxiety Disorder in Adults
Start with either escitalopram or sertraline as first-line SSRI treatment for generalized anxiety disorder in adults. These agents have the strongest evidence for efficacy and tolerability, with escitalopram showing superior efficacy in network meta-analyses and both demonstrating favorable acceptability profiles 1, 2.
First-Line SSRI Selection
SSRIs are the recommended first-line pharmacotherapy for GAD, supported by high-certainty evidence showing a 41% greater treatment response compared to placebo (NNTB = 7) 3. While guidelines suggest the SSRI class broadly 4, specific agent selection matters:
- Escitalopram: Demonstrates the best efficacy among SSRIs with a weighted mean difference of -3.2 on the Hamilton Anxiety Scale 2
- Sertraline: Preferred alongside escitalopram for older adults due to favorable side effect profile 1
Starting Doses
While the provided evidence doesn't specify exact starting doses, standard clinical practice dictates:
- Escitalopram: Start 5-10 mg daily
- Sertraline: Start 25-50 mg daily
Titrate slowly over 2-6 weeks to minimize initial anxiety activation, as SSRIs demonstrate logarithmic response with clinically significant improvement by week 6 and maximal benefit by week 12 5.
Alternative First-Line Options
If avoiding sexual side effects is a priority in relatively healthy adults, buspirone represents an alternative first-line option 1. However, SSRIs remain the primary recommendation given their superior evidence base.
Second-Line Approaches
If response to the initial SSRI is inadequate after 8-12 weeks at therapeutic doses:
- Switch to a different SSRI (fluoxetine, fluvoxamine, paroxetine) 1, 6
- Switch to an SNRI (venlafaxine or duloxetine) - these show comparable efficacy to SSRIs with duloxetine demonstrating particularly strong efficacy in network meta-analyses 2, 6
The SNRI class also receives guideline support as first-line treatment, though with slightly lower certainty of evidence 4.
Critical Implementation Points
Monitor closely during the first 2-4 weeks for behavioral activation, increased anxiety, and suicidal ideation (particularly in patients under age 25). The FDA boxed warning indicates a 0.7% absolute risk increase for suicidal thinking, yielding an NNH of 143 compared to NNTB of 3 for response 5.
Common adverse effects include nausea, diarrhea, headache, insomnia, and sexual dysfunction. More participants discontinue SSRIs due to adverse effects compared to placebo (NNTH = 17), though overall acceptability is equivalent to placebo 3.
Treatment duration: Continue for at least 12 months after achieving response 7. Premature discontinuation is a common pitfall leading to relapse.
Evidence Strength
The recommendation for SSRIs rests on high-certainty evidence from multiple sources including a 2025 Cochrane review of 37 RCTs with 12,226 participants 3, recent network meta-analyses 2, and consensus guidelines from major psychiatric societies 4. The evidence consistently demonstrates SSRIs reduce GAD symptoms more effectively than placebo while maintaining acceptable tolerability.
Avoid benzodiazepines as first-line treatment despite their efficacy, particularly in older adults, due to risks of dependence, cognitive impairment, and falls 1.